Drug Combination Details
| General Information of the Combination (ID: C72898) | |||||
|---|---|---|---|---|---|
| Name | Aloin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Secretion | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Secretion | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Secretion | TNF | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Inhibition | DOX-induced rise in MAB | ||||
| In-vivo Model | Male Wistar rats (150-200 g, age 6-8 weeks) were used in this study. | |||||
| Experimental
Result(s) |
Aloin alleviates doxorubicin-induced cardiotoxicity in rats by abrogating oxidative stress and pro-inflammatory cytokines. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Aloin alleviates doxorubicin-induced cardiotoxicity in rats by abrogating oxidative stress and pro-inflammatory cytokines. Cancer Chemother Pharmacol. 2020 Sep;86(3):419-426. | |||
